Phosphoinositide-dependent kinase-1 (PDK1) is a serine/threonine protein kinase that phosphorylates members of the conserved AGC kinase superfamily, including AKT and protein kinase C (PKC), and is implicated in important cellular processes including survival, metabolism and tumorigenesis. In large cohorts of nevi and melanoma samples, PDK1 expression was significantly higher in primary melanoma, compared with nevi, and was further increased in metastatic melanoma. PDK1 expression suffices for its activity, owing to auto-activation, or elevated phosphorylation by phosphoinositide 3 0 -OH-kinase (PI3K). Selective inactivation of Pdk1 in the melanocytes of Braf V600E ::Pten -/or Braf V600E ::Cdkn2a -/-::Pten -/mice delayed the development of pigmented lesions and melanoma induced by systemic or local administration of 4-hydroxytamoxifen. Melanoma invasion and metastasis were significantly reduced or completely prevented by Pdk1 deletion. Administration of the PDK1 inhibitor GSK2334470 (PDKi) effectively delayed melanomagenesis and metastasis in Braf V600E ::Pten -/mice. Pdk1 -/melanomas exhibit a marked decrease in the activity of AKT, P70S6K and PKC. Notably, PDKi was as effective in inhibiting AGC kinases and colony forming efficiency of melanoma with Pten wild-type (WT) genotypes. Gene expression analyses identified Pdk1-dependent changes in FOXO3a-regulated genes, and inhibition of FOXO3a restored proliferation and colony formation of Pdk1 -/melanoma cells. Our studies provide direct genetic evidence for the importance of PDK1, in part through FOXO3a-dependent pathway, in melanoma development and progression. www.nature.com/onc Pdk1 required for melanoma development and metastasis M Scortegagna et al Pdk1 required for melanoma development and metastasis M Scortegagna et al
INTRODUCTION
Phosphoinositide-dependent kinase-1 (PDK1) is a serine/threonine protein kinase that phosphorylates over 20 members of the conserved AGC kinase superfamily, including members of the protein kinases A (PKA), G (PKG, including PKB/AKT) and C (PKC) families. 1, 2 PDK1 is activated upon phosphorylation of a threonine or serine residue in the activation loop (T-loop), which is mediated by either auto-phosphorylation or by the phosphoinositide 3 0 -OH-kinase (PI3K). 3 Consequently, PDK1 activity can be dependent on phosphatidylinositol-3,4bisphosphate (PtdIns-3,4-P2) and phosphatidylinositol-3,4-5trisphosphate (PtdIns-3,4,5-P3), the lipid products of PI3K, which requires it to anchor to the plasma membrane. 4, 5 It can also function independently of anchoring to the membrane as an active kinase through its auto-activation. 4, 5 Accordingly, PDK1 is an important regulator of cellular processes, including protein translation, cell survival, metabolism and tumor development and progression.
In cancer, PDK1 activation has been associated with genomic and epigenetic mechanisms. A gain of the 16p13.3 locus, which spans the PDPK1 region harboring the PDK1 gene, was found in lymph node metastasis and in castration-resistant prostate cancer samples, 1 has been associated with poor differentiation of latestage lung cancer 2 and with poor prognosis of breast cancer patients. 4 Increased PDK1 activity is implicated in enhanced tumor cell proliferation, reduced apoptosis and angiogenesis. 4, 5 PDK1 was shown capable of augmenting tumorigenesis in tissues harboring ERBB2 amplifications, 4 PTEN deletions 5 and mutations in the catalytic subunit of phosphoinositide 3-kinase (PIK3CA). 6 Inhibition of PDK1 is therefore expected to attenuate tumors associated with deregulated PIK3CA/PTEN signaling. Indeed, hypomorphic mutation of PDK1 in Pten þ /mice delays the onset of tumorigenesis, 7 and small-molecule inhibitors of PDK1 inhibit tumor xenografts and lung colonization. 8, 9 Further, Pdk1 inactivation effectively attenuated the development of Kras oncogene-driven pancreatic cancer, but not non-small cell lung carcinoma, 10 further supporting the importance of PDK1 in tumor development, albeit, in select cancer types. PDK1 expression in melanoma has not been assessed nor was the significance of its genetic inactivation for melanoma development and progression evaluated.
Crosstalk between the mitogen-activated protein kinase and AGC signaling pathways has been implicated in the development and progression of melanoma and for its resistance to therapy. [11] [12] [13] Our earlier studies showed that crosstalk between PKC and c-Jun N-terminal kinase augments the activities of c-Jun N-terminal kinase, 14 and that crosstalk between extracellular-signal-regulated kinase and c-Jun increases both the transcription and activity of c-Jun. 15 c-Jun is an important transcriptional activator of PDK1. 16 Notably, the expression of PDK1 is sufficient to restore tumor growth after c-Jun knockdown in melanoma cells, 16 suggesting that PDK1 is an important mediator of c-Jun oncogenic activities.
To assess the role of PDK1 in melanoma formation and progression, we used a genetic mouse model driven by melanocyte-specific expression of Braf V600E and inactivation of Pten, achieved using the Tyr::CreER transgene that encodes conditionally active CreER T2 specifically in melanocytes. These mice develop melanoma with 100% penetrance, short latency and with metastases in the lymph nodes, lungs and spleen. 17, 18 Given the relevance of the Cdkn2a locus in melanoma, we have also developed a new model in which the Cdkn2a locus has been deleted on the background of the Braf/Pten mutant animals.
RESULTS
Inactivation of Pdk1 prolongs latency and reduces the size of Braf/Pten melanoma Systemic administration of 4-hydroxytamoxifen (4-HT) to the Tyr:: CreER::Braf V600E ::Pten lox/lox and Tyr::CreER::Braf V600E ::Cdkn2a lox/lox :: Pten lox/lox mice (days 1, 3 and 5 following birth) resulted in the appearance of highly pigmented lesions within 7-10 days (Figure 1a , Supplementary Figures S1c and S2e,f). Selective inactivation of Pdk1 in the melanocytes and tumors developed in these animals (see Supplementary Figures S1a,b,d) delayed the development of pigmented lesions increasing the overall survival (17 days in Braf V600E :: Cdkn2a -/-::Pten -/-::Pdk1 þ / þ and 20 days in Braf V600E ::Pten -/-::Pdk1 þ / þ versus 26 days in Braf V600E :: Cdkn2a -/-::Pten -/-::Pdk1 -/and 28 days in Braf V600E ::Pten -/-::Pdk1 -/animals; Figure 1b and Supplementary Figure S2a ). Correspondingly, rate of melanocyte proliferation was markedly attenuated (B80%; Figure 1c ). Histological analysis of primary skin lesions revealed highly pigmented cells with variably shaped enlarged nuclei (Figure 1d and Supplementary Figure S2b ), which were confirmed to be of melanocytic origin by immunostaining for tyrosinase ( Figure 1e ). The number of pigmented melanoma cells found throughout the dermis and subcutis with pagetoid spread into the epidermis was decreased in the Pdk1 -/genotype ( Figure 1d ), providing the initial indication that PDK1 has a role in melanocyte biology (that is, pigmentation) and transformation.
Notably, inactivation of the cell cycle regulator Cdkn2a in Braf V600E ::Pten -/mice results in more aggressive and faster growing tumors, consistent with the known role of Cdkn2a in melanoma development. Significantly, the contribution of Pdk1 to melanoma development was even more pronounced in the Braf V600E ::Pten -/-::Cdkn2a -/mice, as shown by the increased survival rate upon inactivation of Pdk1 ( Figure 1b ).
Local, rather than systemic, administration of 4-HT to adult animals (day 21) allows tumor formation to be monitored at the point of application. 17 As was observed upon systemic administration of 4-HT, overall survival was prolonged by Pdk1 deletion (Supplementary Figure S1e) , from 59 to 88 days for the Braf V600E ::Pten -/-::Cdkn2a þ / þ mice and from 47 to 82 days for the Braf V600E ::Pten -/-::Cdkn2a -/mice (Figure 1f and Supplementary Figure S2c ). The tumor volumes in these mice were also markedly reduced upon Pdk1 inactivation, from 1400 mm 3 to 300 mm 3 in Braf V600E ::Pten -/-::Cdkn2a þ / þ and from 2000 mm 3 to 400 mm 3 in the Braf V600E ::Pten -/-::Cdkn2a -/mice ( Figure 1g ). Moreover, the rate of melanocyte proliferation was reduced by 50% and cell death was increased threefold by Pdk1 inactivation in Braf V600E ::Pten -/mice (Figures 1h and i). A decreased nuclear to cytoplasmic ratio, often associated with altered PDK1/AGC kinase activity, was noted in the Pdk1-deficient melanomas (see Supplementary Figure S2d ).
The median survival time of Braf V600E ::Pten -/mice was extended by inactivation of Pdk1 by B40% (from 20 to 28 days) in animals receiving 4-HT systemically (Supplementary Figure S2a ) and by B55% (from 52 to 82 days) in mice with locally administered 4-HT (Supplementary Figure S2b ). These findings provide genetic evidence for the involvement of Pdk1 in melanoma development, as reflected by the longer disease latency and reduced tumor size in the Pdk1 -/genotypes. Analysis of Pdk1 þ / À genotypes did not reveal such differences (data not shown), suggesting that the partial inhibition of Pdk1 may not suffice to inhibit melanoma development and or progression.
Pdk1 is required for melanoma metastases Mice that received 4-HT systemically showed evidence of melanoma spread into the regional lymph nodes and had lung and spleen metastases, consistent with earlier reports. 17 Metastasis to lymph nodes, lungs and spleen was significantly lower in the Pdk1 -/genotypes of both mouse models, with a more pronounced inhibition seen in the Braf V600E :: Pten -/-::Cdkn2a -/animals (Figures 2a-c, Supplementary Figures S2e,f). Independent assessment for the degree of metastases was performed by staining lymph nodes and lungs with S100, a marker with excellent sensitivity for pigmented and amelanotic melanoma (Figures 2e and f) , although within the lymph node compartment it may also stain follicular dendritic cells, which are distinguishable based on the cytologic features and location within the lymph node. Melanin, however, is remarkably good at absorbing light and therefore S100 stain could not detect those clusters of tumor cells with strong melanin pigmentation that were easily detected by hematoxylin and eosin (H&E). Notably, quantitation based on both S100 immunofluorescence and H&E staining revealed a pronounced inhibition of metastases in the Braf V600E ::Pten -/-::Cdkn2a -/animals (Figures 2a-c,e and f). Similarly, metastatic lesions in lymph nodes of animals subjected to local 4-HT administration were also significantly inhibited by the deletion of Pdk1 (B80% reduction) ( Figure 2d and g). These findings suggest that Pdk1 has a critical role in metastasis of the Braf V600E ::Pten -/melanoma. The inhibition of metastasis is likely to be uncoupled from the delay in tumorigenesis, as degree of inhibition seen in lymph nodes and lungs was remarkable, likely to be independent of delayed proliferation.
Key AGC kinases and FOXO3a mediate Pdk1 signaling in melanomagenesis
To determine the molecular mechanisms by which PDK1 contributes to melanomagenesis, we analyzed changes in key signaling pathways associated with PDK1. Tumors and tumorderived primary cultures from Braf V600E ::Pten -/-::Cdkn2a -/-::Pdk1 -/mice showed markedly decreased phosphorylation of AKT T308 , the primary PDK1 phosphoacceptor site, and of the AKT substrates PRAS40 and glycogen synthase kinase 3b (GSK3b) (Figure 3a ), demonstrating that AKT signaling is significantly reduced in the absence of functional PDK1. AKT analysis was performed using pan AKT antibodies, recognizing all three AKT forms. Correspondingly, the phosphorylation of S6K, another AGC kinase substrate for PDK1, was markedly attenuated (Figure 3b ). We expect that other AKT substrates were also affected upon PDK1 inactivation. Members of the PKC family are also among the AGC kinases that require phosphorylation by PDK1 for maturation, stabilization and subsequent activation. 19, 20 Consistent with this, both the level and extent of phosphorylation of PKC were notably lower in Braf V600E ::Pten -/-::Cdkn2a -/-::Pdk1 -/melanomas, whereas the decrease observed in ribosomal S6 kinase phosphorylation was not ( Figure 3b ). These findings demonstrate that Pdk1 inactivation in melanocytes impairs key AGC signaling pathways.
We next performed a non-biased assessment of changes in gene expression in melanomas from Pdk1-inactivated Braf V600E ::Pten -/-::Cdkn2a -/mice by performing gene expression profiling analysis. Principal component analysis for the microarray data confirmed that Pdk1 inactivation appeared to be the most significant effect as the biological replicates in each group were clustered together (Supplementary Figure S3a ). To identify the differentially expressed genes, linear modeling and empirical Bayesian statistics approaches were applied. 21 Genes with both a P-value below 0.05 and a change over ± twofold were considered statistically different between Braf V600E ::Pten -/-::Cdkn2a -/-::Pdk þ / þ and Braf V600E ::Pten -/-::Cdkn2a -/-:: Pdk1 -/groups, and a total of 827 significant differentially expressed genes were identified. As shown in the heat map (Figure 3c ), 431 genes were upregulated in Pdk1-knockout tumors ( Supplementary  Table S1 ) and 396 were downregulated ( Supplementary Table S2 ). Network and functional analyses using Ingenuity Pathways Analysis (Ingenuity Systems) revealed that these up-and down-regulated genes were classified into a number of functional groups. Among canonical pathways found to exhibit the significant enriched (Fisher test -valuep0.05) in upregulated genes are Interleukin-6, Po0.0005. The quantification of tumor metastasis was performed using immunohistochemical and H&E stains in a blinded manner by an expert histopathologist (MB). Pigment deposition in lung metastases correlates well with tumor deposits in the lung but does not in lymph nodes, where melanin pigment-laden macrophages are commonly observed in lymph node sinuses. Lung metastases were uniformly small (less than 0.5 mm) occurred as clusters of tumor cells. These clusters were counted on a full cross section of the lung to quantitate metastatic burden. The lymph node deposits in Pdk1 WT (and untreated) melanomas were larger and more irregular, so the percentage of the cross sectional area of a full section of lymph node was used to determine metastatic burden to lymph nodes. (d) Representative H&E stain of lymph node after local induction of melanoma in Braf V600E ::Pten -/-::Cdkn2a -/for Pdk1 WT and Pdk1 KO genotypes. Eight lymph nodes were quantified from eight animals for each group. Interleukin-10, eicosanoid and glucocorticoid receptor signaling as well as fibrosis-associated pathways ( Supplementary Table S3 ). In contrast, pathways associated with cell cycle, DNA replication, mitosis and the DNA-damage response were significantly enriched in the downregulated gene set in the Pdk1-knockout tumors ( Supplementary Table S4 ). The changes observed for representative genes from each of the major three clusters were validated by quantitative PCR (qPCR) analysis (Supplementary Figure S3c) .
Interestingly, a number of these upregulated and downregulated genes are commonly regulated by the transcription factor FOXO3a (Supplementary Figure S3b) , which is negatively regulated by PDK1 substrates AKT or serum-and glucocorticoid-regulated kinase (SGK). PDK1-dependent changes in transcription of the FOXO3a-related gene set were confirmed by qPCR, whereas no changes were observed in pigmented genes expression (Supplementary Figure S3c) . Furthermore, immunostaining of tumor sections revealed strong nuclear localization of FOXO3a in Pdk1 -/tumors, which correlated with reduced AKT phosphorylation (Figure 3d ), as this kinase has been implicated in the control of FOXO3a phosphorylation-dependent nuclear export. 22, 23 These findings suggest that Pdk1 inactivation and concomitant inhibition of AKT activity cause nuclear retention and transcriptional activation of FOXO3a. Nuclear cytoplasmic fractionation of primary melanoma cell lysates confirmed Figure 3f ) and partially restored the ability of melanoma cells to form colonies (Figure 3g ), whereas attenuating changes in the expression of FOXO3a-related genes identified in the gene expression microarrays (Figure 3h) . These results establish a regulatory link between PDK1 and FOXO3a and demonstrate its role in melanoma development and progression.
PDK1 inhibitor phenocopies genetic inactivation
Combinations of PI3K/AKT signaling inhibitors and targeted therapies against BRAF are currently being evaluated in clinical trials for melanoma. Therefore, we asked whether the attenuation of PDK1 activity with the available PDK1 inhibitors (PDKi) would phenocopy the genetic inactivation of Pdk1 in the Braf V600E ::Pten -/animals. For this, we tested the efficacy of the PDKi GSK2334470 [24] [25] [26] (Supplementary Figure S4a ) in newborn Braf V600E ::Pten -/mice subjected to systemic administration of 4-HT. Twice weekly administration of PDKi resulted in marked inhibition of pigmented lesions and concomitant melanomagenesis (Figure 4a ), as well as significant inhibition of lung metastases, seen by H&E stainingbased quantification (B80%, Figure 4b ), and lymph node metastases as by S100 immunostaining (Figure 4c ), similar to the phenotype seen upon genetic ablation of Pdk1 (Figures 2a,b) . AKT, but not PKC, signaling was also efficiently inhibited in primary tumor cells ( Supplementary Figure S4b) . Further, immunohistochemistry analysis of skin from mice treated with PDKi revealed a marked decrease in pAKT308 (Figure 4d ). It is noteworthy that although the administration of PDKi did not inhibit the development of localized melanomas (local application of 4-HT), it reduced metastasis burden in lymph nodes as quantitated by S100 stain (Figure 4e ). The reduced effectiveness of PDKi in locally induced melanomas suggests that either the route/frequency of administration and/or dose of PDKi may be insufficient, or that alterations in signaling in melanoma developed in the adult animals (for example, increased local PI3K signaling 24, 27 ) may have limited PDKi efficacy. It is also possible that enzymes not affected by the PDKi (that is, PKC 27 ) may have more pronounced roles in locally induced melanomas. 25, 26 We also compared the effect of PDKi on human melanoma cell lines with wild type (WT) versus inactivated Pten (IC 50 estimated to be o10 mM for these cell lines). Notably, melanoma cells with inactivated Pten exhibited increased phosphorylation of the PDK1 substrates AKT, when compared with melanoma cells carrying WT Pten. Yet, PDKi effectively attenuated AKT T308 and p70S6K phosphorylation, as well as the phosphorylation of the AKT downstream substrate PRAS40, the phosphorylation of the SGK downstream substrate NDRG1 (N-myc downstream-regulated gene 1), and phosphorylation of the AKT/SGK substrate FOXO3a, independent of the Pten mutation (Figure 5a ). Notably, inhibition of phosphorylated PRAS40 was seen upon PDKi treatment despite increased AKT S473 phosphorylation; the latter was previously reported and attributed to mTORC2 (mTOR Complex 2). 24 These findings suggest that PDKi effectively attenuates number of key AGC kinases and respective substrates, independent of Pten status and AKT activity. Correspondingly, the colony formation assay was used to assess clonal growth of the human melanoma cell lines Lu1205 (Pten inactive) and WM35 (Pten WT) that were either treated with vehicle or PDKi. Notably, PDKi decreased the size of colonies in both Pten WT and mutant melanomas, compared with the vehicletreated cells (Figure 5b) . These data suggest that pharmacological inhibition of PDK1 is as effective in attenuating AGC kinases activated in both Pten WT and mutant melanoma cells.
Increased PDK1 expression in metastatic human melanoma We used tumor microarrays to determine whether PDK1 expression levels correlate with melanocytic neoplastic progression and clinical outcome. Using a standard H score system we found that over 90% of the positive tissue samples expressed PDK1 in both cytoplasmic and nuclear compartments (Figure 5c ). This analysis of more than 700 tumors revealed significantly higher expression of PDK1 in melanomas compared with nevi ( Figure 5d ; Po0.001). Similarly, expression was higher in metastatic relative to primary melanoma specimens and higher in melanomas than in nevi (Figure 5c ; Po0.001 for both comparisons). No association was found between PDK1 expression and melanoma-specific survival within the primary or metastatic subsets. PDK1 expression was higher in lesions thicker than 1 mm (P ¼ 0.01) and in ulcerated lesions (P ¼ 0.004). These findings substantiate the importance of PDK1 in melanoma development and progression and point to its possible use as a marker in melanoma.
DISCUSSION
Growing evidence points to the activation of PDK1 in cancer, through genomic or epigenetic changes, often associated with more aggressive tumors and poorer prognosis. 1, 2, 4 Consistent with these reports, genetic inactivation of Pdk1 resulted in effective inhibition of Kras-driven pancreatic cancer but not in non-small cell lung cancer. 10 The present study provides the first genetic evidence for the importance of PDK1 in melanoma. Genetic inactivation of Pdk1 delayed the onset of melanomas and almost completely abolished metastases in both the systemic and local Braf V600E ::Pten -/mouse melanoma models. Gene expression profiling has pointed to the possible role of FOXO3a in Braf V600E ::Pten -/-::Cdkn2a -/-::Pdk1 -/melanomas, a finding that was confirmed upon inhibition of FOXO3a expression, which restored the tumor cells' ability to form colonies in culture. As both AKT and SGK1 are capable to phosphorylate and cause nuclear exclusion of FOXO3a, further studies will determine the possible role of SGK1 in FOXO3a regulation in melanoma cells. Further, PDK1 inhibition was as effective on the AGC kinase AKT, SGK, P70S6K, and downstream substrates NDRG1 and FOXO3a, in both Pten WT and mutant melanomas, indicating that the core components of the PDK1 pathway are equally inhibited, independent of AKT phosphorylation. Future studies could elaborate on the role of distinct AGC kinases in melanoma harboring different genetic backgrounds (that is, Pten WT, Cdkn2a WT or Nras mutant). The genetic data supporting an important role for PDK1 in melanoma development and metastasis are supported by the use of PDKi. The administration of PDKi to systemically activated Braf V600E ::Pten -/-::Cdkn2a -/animals, effectively reduced melanomagenesis and metastatic load, phenocopying the genetic inactivation. Notably, PDKi was not effective in the inhibition of tumors initiated in the local model, suggesting that either improved efficacy or combination with other inhibitors would be warranted. The possibility that exposure of PDKi may result in mTORC-2-driven AKT activation and AKT-driven resistance was recently proposed. 25 Although this possibility was not evaluated in the present study, we also observed increased AKT S473 phosphorylation, upon PDKi treatment, albeit, with effective inhibition of PRAS40 phosphorylation, a primary AKT substrate. Partial inhibition of Pdk1, as seen in the heterozygous Braf V600E ::Pten -/-::Pdk1 þ /animals, was not sufficient to inhibit metastases and delay tumor development, indicating that efficient inhibition of PDK1 and its downstream targets will be required for achieving an effective therapeutic index. It is important to note that neither the tissue-specific genetic inactivation nor the general pharmacological inhibition of PDK1 results in toxicity, implying that higher doses and more potent PDKis can be tolerated. These findings suggest that PDKis could be tested in clinical trials, possibly in combination with BRAF inhibitor or MEK inhibitor. Accordingly, an intervention study with mice that have established large tumors showing the effectiveness of PDKi alone with BRAF inhibitor would substantiate the clinical utility of this approach. It should be noted that some studies targeting PDK1 with small-molecule inhibitors or RNA interference failed to show efficacy in cancer models. 28, 29 This difference suggests that PDK1 inhibition may affect tumor growth and metastases via mechanisms that vary with cancer type and involve microenvironmental factors (for example, stroma or innate immunity), which are lacking in commonly used xenograft models. Taken together, our demonstration that PDK1 and its downstream effectors have a critical role in melanoma development and metastases offers new opportunities for evaluation of therapeutic modalities for melanoma and other tumors expressing high levels of PDK1.
MATERIALS AND METHODS

Primary melanoma cells
Murine melanoma cells from Braf V600E ::Pten -/-::Cdkn2a -/tumors were derived by physical resection of primary cutaneous lesions. Cell suspensions were plated in media (Dulbecco's modified Eagle Medium) 
Histological analyses
Tumors and sections were fixed in Z-fix (Anatech, Battle Creek, MI, USA) overnight, washed twice with phosphate-buffered saline and processed for paraffin embedding. Sections were sliced at 5 mm and stained with H&E.
Antibodies and reagents
Antisera against TYRP1 (tyrosinase-related protein 1) was a kind gift from Dr Hearing (National Cancer Institute). Anti-cleaved caspase 3, pNDRG1, pPDK1, pAKT308, pAKT473, pGSK3b (Ser 9), pPRAS40 (Thr 246), pFOXO3a (Thr 32), pERK1/2, AKT, FOXO3a, pPKC pan (g Thr514), pS6K (Thr389) and pRSK (Ser 227) were purchased from Cell Signaling Technologies (Danvers, MA, USA). Monoclonal anti b-actin, anti-lamin A/C and tubulin were purchased from Santa Cruz (Santa Cruz, CA, USA). Antibodies against Ki-67 and 4-HT were purchased from Sigma (St Louis, MO, USA). Antibodies to S100 were obtained from Dako (Carpinteria, CA, USA).
Gene silencing and transfection
Pre-designed small interfering RNA for mouse FOXO3a (NM_019740) was purchased from Ambion (Austin, TX, USA), and small interfering RNA was transfected with Lipofectamine RNAiMAX (Invitrogen, Grand Island, NY, USA) according to protocol supplied by the vendor. Mouse FOXO3a small hairpin RNA constructs were from Open Biosystems (Huntsville, AL, USA) (TRCN0000071614 and TRCN0000071617). pLKO.1 empty vector was used for control cells. The cells were selected in full-media containing 1.5 mg/ml puromycin.
Western blotting
To extract whole-cell lysate, cells were harvested using immunoprecipitation assay buffer. Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis and proteins were transferred onto a nitrocellulose membrane (Osmonics Inc., Minnetonka, MN, USA). The membrane was probed with primary antibodies followed by a secondary antibody conjugated with fluorescent dye and detected by the Odyssey detection system (Amersham/Bioscience, Piscataway, NJ, USA). 
Nuclear and cytoplasmic lysate extraction
The fractionation was done using the nuclear extract kit from Active Motif (Carlsbad, CA, USA) following the manufacturer's protocol. 
Immunohistochemistry and immunofluorescence
Tissue microarray analysis
Tissue microarrays consisting melanoma or nevi cohorts were previously described, 30 and were stained using PDK1 antibodies (Abcam). Briefly, tissue microarray consist of 747 neoplastic lesions (209 primary cutaneous, 312 metastatic or cutaneous origin and 226 nevi). PDK1 levels were measured by a dermatopathologist, who scored the intensity on a scale of 0-3. Expression in the nucleus and cytoplasm was concordant, and therefore a single score was included for each patient. The percent of cells staining positive for PDK1 expression was multiplied by the intensity score, which provided scores that ranged between 0 and 300. (that is, intensity score of 2 seen in 75% of cells provides an H score of 150, intensity score of 1 in 50% of cells yields an H score 50).
Microarray analysis
RNA (500 ng) from each experimental group was pooled to enable four biological replicates and used for the synthesis of biotin-labeled cRNA using an RNA amplification kit (Ambion). The cRNA labeled with streptavidin-Cy3 was used for hybridization with the Mouse Ref-8 v2.0 Expression BeadChip (Illumina, San Diego, CA, USA) (B25 K mouse transcripts). The BeadChips were scanned and data were preprocessed by Illumina GenomeStudio software without background correction or normalization (threshold detection P-values ¼ 0.05). The redefined list consisted of 15 922 probes detected in the experimental samples. Raw data were log2-transformed and quantile normalized using neqc function in limma package. 31 To identify differentially expressed genes, the linear modeling approach and empirical Bayes statistics as implemented in the limma package were used. 21 The Benjamini-Hochberg method was used to correct for the multiple comparison errors. 32 Principal component analysis was performed with Partek Genomics Suite (Partek Inc., St Louis, MO, USA), and hierarchical clustering and other statistical analyses were performed using R/Bioconductor. 33 Genes with at least a twofold change at the 95% confidence level were considered as significant. Functional enrichments were performed using (IPA) software (Ingenuity Systems Inc., Redwood City, CA, USA). The microarray data were deposited in the NCBI (National Center for Biotechnology Information) GEO database, accession number GSE42187.
Quantitative Reverse Transcription-PCR analysis
Total RNA was extracted using a total RNA miniprep kit (Sigma) and digested with DNase I. Complementary DNA was synthesized using oligo-dT and random hexomer primers for SYBR Green QPCR analysis. H3.3A were used as internal controls. At least triplicate biological samples were used for the QPCR analysis. The PCR primers were designed using the Primer3 software and their specificity was checked using BLAST. The PCR products were limited to 100-200 bp. The sequence of the primers used for QPCR analysis are available upon request.
BrdUrd incorporation
Mice were injected i.p. (intraperitoneal) with 100 mg/kg BrdUrd (Sigma). Tissue was collected 3 h after BrdUrd injection for the measurement of cell replication. Incorporated BrdUrd was detected as described above.
Quantification of lymph node and lung metastasis
Metastases to lymph nodes were observed only 2-5 weeks following primary tumor induction, restricted to draining lymph nodes, supporting metastasis from a regional primary tumor. Fixed and embedded lung tissues were sliced to obtain five serial sections per lung. H&E stain was used to quantify the number and size of metastases under a histology microscope. For lymph node metastases, H&E-stained lymph node was photographed and analyzed with ImageJ (NIH, Bethesda, MD, USA). Percent lymph node involvement was defined as the surface area of the sub-capsular tumor metastasis relative to the surface area of the entire lymph node. For quantitation of S100-positive cells, all slides were scanned at a magnification of Â 20 using the Aperio ScanScope FL system (Aperio Technologies, Vista, CA, USA) and quantified using the 'Area Quantification FL' algorithm (version 11 Aperio Technologies) the algorithm was 'tuned' using a preset procedure and the subsequent macro was saved and applied to all slides. For quantitation of BrdU, cleaved caspase 3 and S100positive cells along with DAPI-positive cells were counted in six random Â 20 fields per mouse.
Colony assay formation
Five hundred cells were plated into six-well plates. After 7-12 days in culture, viable colonies were stained with Cristal Violet (Sigma-Aldrich). Colony number and size were determined using ImageJ.
Statistical analysis
The data were analyzed by unpaired t-test and Po0.05 was considered statistically significant. Kaplan-Meyer survival curve was compiled using Prism statistical analysis software (San Diego, CA, USA). Significance was assessed using the Log-rank (Mantel-Cox) test.
Synthesis of PDKi GSK2334470
